Celcuity Inc.
Clinical-stage biotech developing targeted therapies for multiple solid tumors.
CELC | US
Overview
Corporate Details
- ISIN(s):
- US15102K1007
- LEI:
- Country:
- United States of America
- Address:
- 16305 36TH AVENUE N, 55446 MINNEAPOLIS
- Website:
- https://www.celcuity.com/
Description
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company's approach centers on the PI3K/AKT/mTOR (PAM) pathway, a critical signaling cascade involved in cancer cell growth and survival. Its lead product candidate, gedatolisib, is a potential first-in-class, pan-PI3K and mTORC1/2 inhibitor designed to comprehensively blockade the PAM pathway. Celcuity's pipeline is advancing treatments with a focus on breast and prostate cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Celcuity Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celcuity Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celcuity Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
